About the FDA possibly slow rolling us in lieu of a focus
About the FDA possibly slow rolling us in lieu of a focus on big pharma...
My take is that they aren't actively making it more difficult for us, they're just actively making it easier for big pharma.
Big pharma has lobbyists. They have connected people on their board or as consultants. They have been through the process often enough to know people and possibly even their wives/husbands by name. They have more people working on every facet of the process to speed things up.
In comparison nobody knows us, we have no real connections anywhere, and we have far fewer resources available.
None of us are inclined to automatically believe anything a complete stranger tells us, even if they have initials behind their name. Unless we are seeking them out through our own due diligence. But if we're given the name of an otherwise complete stranger from someone we know or trust, we'll automatically allow them some benefit of the doubt. Big pharma is well known, well connected, and as a result they have an easier time navigating the process.
But the FDA will be happy to help us to market if we can pass all of their tests without a shadow of doubt. After that our doubt status will begin to change and we'll see the benefit of that shake out with label extensions and future interactions that come along much easier.
#DaytimeRespert24
11
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Driving Under the Stars with the K7 Pro Let's be real here, night driving can give anyone a touch of the heebie-jeebies. Crunch time on the road when the lights dim and the stakes rise. Enter the Wolfbox K7 Pro, tailormade for these nocturnal journeys. This dash cam's no slouch—it packs a punch with true-blue 4K recording front and back. We're talking sharp images, even...
Continue Reading
Navigating Inflationary Waters: A Maple Leaf Foods Update Seeing Maple Leaf Foods (TSX: MFI) push through a tough inflationary landscape with a 15.4% rise in EBITDA would make any seasoned investor nod in respect. They've gone from last year's $111.7 million to a hefty $129 million in Q3 2026. What's more, their EBITDA margin climbed to 12.5%, up 140 basis points from...
Continue Reading
Shuffling Pieces in Healthcare Management Change is constant in healthcare management, folks, and it's all about finding the right puzzle pieces. That's what Assembly Health has done by welcoming Grant Davis as their new Chief Experience Officer (CXO). Yeah, you heard me right. It's not a CEO or a CFO, but the CXO role that's under the spotlight this time around, aiming...
Continue Reading
When Makeup Meets Pajamas: The Perfect Storm Picture this: a makeup brand and a lifestyle label dreaming up a collaboration that sends consumers into a full-blown frenzy. In a whirlwind that lasted just 60 seconds, tarte's latest partnership with Roller Rabbit blazed through stock, cementing its place as a record-breaking phenomenon. Maureen Kelly, tarte’s intrepid CEO,...
Continue Reading
What's Really Going On with BWIN, LFCR, and PCRX? Everyone talks about when there's smoke, there's fire. But in this case, it’s hard not to wonder if we're standing knee-deep in burning embers, or just a dusty old campfire. Halper Sadeh LLC is ringing the alarm bells for Baldwin Group, Lifecore Biomedical, and Pacira BioSciences, the trio tagged under NASDAQ: BWIN,...
Continue Reading
Turning the Election Tide in Illinois Damn, if you're not paying attention to what's shaking in Illinois, it's time to listen up. The Democrats under Speaker Emanuel "Chris" Welch are strutting their stuff, leaving an indelible mark on the political landscape. An eye-popping $35 million in campaign dough was raised, safeguarding every Democratic incumbent and managing to...
Continue Reading
Legal Battles Loom Over UP Fintech UP Fintech Holding Limited, trading under NASDAQ: TIGR, is knee-deep in legal mire, thanks to a hefty class action lawsuit. Levi & Korsinsky rings the legal bells for shareholders who grabbed TIGR securities from April 22, 2024, to June 2, 2026. The heat is on—a December 28, 2026 deadline for lead plaintiff spot beckons. Dust off those...
Continue Reading
The 11th Global Mazu Culture Forum kicked off on November 1 in Putian City, Fujian Province—smack dab on the historical Meizhou Island. This ain’t just another talk-fest; it's a melting pot of ideas and achievements packaged with cultural flair and some serious tech muscle. Nestled in China's southeast, Meizhou Island serves as the heartland for Mazu culture, a beacon...
Continue Reading
Everyone's been dreaming about jackpot profits, huh? Well, for those holding onto Gildan Activewear Inc. (NYSE: GIL) shares, that bubble just popped. We're staring at a class-action lawsuit for securities fraud, accusing the company of cooking the books. Time for Wall Street's soap opera, folks. Understanding the Allegations Let's get to the grit. According to the lawsuit...
Continue Reading
A Weeklong Trail Adventure There's nothing quite like shaking off the cobwebs with a splash of mountain air mixed with a dash of raw athleticism. Salomon Trail Week wrapped up over in Linhai, China, marking yet another notch in the belt of trail running culture. This wasn't just a mere stampede over scenic trails but a full-on celebration of the global and Chinese trail...
Continue Reading
: Revenue Hits $100M - Continue Reading"
aria-label="Continue reading: Fractal Sees Explosive Q2 Gain: Revenue Hits $100M">
Continue Reading